Merck : FDA Approves Bravecto Chewable Tablet For Dogs To Kill Fleas And Ticks

Merck Animal Health, the global animal health business unit of Merck & Co., Inc. (MRK), said that the U.S. Food and Drug Administration has approved Bravecto or fluralaner chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg).

The company noted that Bravecto is the first and only treatment that has been shown to quickly and effectively kill fleas and multiple tick species for 12 weeks in a single dose. Bravecto also is effective for eight weeks against Amblyomma americanum ticks.

The active substance of Bravecto, fluralaner, a new ectoparasiticide belonging to the isoxazoline group, is systemically active against fleas and ticks. Bravecto is presented as a flavored chew that dogs accept readily. The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis or FAD as a direct result of eliminating flea infestations. The most common side effects are mild and transient gastrointestinal effects, the company noted.

According to the company, the most common adverse reactions recorded in clinical trials were vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. Bravecto has not been shown to be effective for 12-weeks' duration in puppies less than 6 months of age. Bravecto is not effective against lone star ticks beyond 8 weeks after dosing.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT